ERIS vs GRANULES: Stock Comparison

Eris Lifesciences Limited vs Granules India Limited

Live data: 28 July 2026, 4:08 PM IST • Source: NSE and company filings

Granules India Limited is the larger company by market capitalisation. Eris Lifesciences Limited shows a lower P/E, a higher ROE and a higher dividend yield, while Granules India Limited shows faster revenue growth, lower leverage and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Eris Lifesciences Limited and Granules India Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, ERIS is more favourable on 8 of 13 scored metrics and GRANULES on 5These counts are context-free and are not an overall rating.

Key Differences

Market Cap
GRANULES is the larger company
₹20,831 Cr vs ₹19,269 Cr
P/E Ratio
ERIS has a lower P/E
31.13x vs 31.63x
P/B Ratio
GRANULES has a lower P/B
4.16x vs 4.94x
EPS
ERIS has higher earnings per share
₹45.24 vs ₹26.92
Dividend Yield
ERIS has a higher dividend yield
1.03% vs 0.21%
Revenue Growth (TTM YoY)
GRANULES has faster revenue growth
22.8% vs 7.1%
EPS Growth (TTM YoY)
ERIS has faster EPS growth
200% vs 31.3%
Qtr Sales Growth
GRANULES has stronger quarterly sales growth
22.8% vs 7.27%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricERISGRANULES
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricERISGRANULES
Live Price₹1,390.8₹845.4
Day Change-0.9%0.31%
Volume52,6407.05 L
52-Week High₹1,885₹910
52-Week Low₹1,200₹432.6
Distance from 52W High-26.22%-7.1%

Valuation

MetricERISGRANULES
Market Cap₹19,269 Cr₹20,831 Cr
P/E Ratio31.13x31.63x
P/B Ratio4.94x4.16x
EPS₹45.24₹26.92
Book Value₹285.48₹205.21
Dividend Yield1.03%0.21%

Growth

MetricERISGRANULES
Revenue Growth (TTM YoY)7.1%22.8%
EPS Growth (TTM YoY)200%31.3%
Qtr Sales Growth7.27%22.8%
Qtr Profit Growth200%44.6%

Profitability & Leverage

MetricERISGRANULES
ROE18.7%13.7%
ROCE14.1%15.5%
Net Margin19.89%11.15%
Operating Margin35.8%22.1%
Debt to Equity0.6x0.3x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricERISGRANULES
Promoter Holding54.14% 0.22 pp37.67%
FII Holding5.75% 0.64 pp17.5% 2.19 pp
DII Holding20.72% 0.37 pp16.11% 0.9 pp
Public Holding19.4% 0.07 pp28.38% 1.28 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Eris Lifesciences Limited and Granules India Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.